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Synthesis and Characterization of Tripodal-Imidazolium and Pyridazine 
Ruthenium Complexes and Their Associated Ligands.  
Jacqueline L. Kowalke, John P. Selegue 
University of Kentucky  
ABSTRACT: Photochemical therapy (PCT) is a relatively new treatment for cancer. PCT, unlike photodynamic therapy (PDT), does not 
require oxygen though it may be one of the mechanisms that the photosensitizer uses to destroy cancerous cells. Ruthenium complexes have 
recently entered clinical trials for the treatment of cancer. TLD1433, a ruthenium coordination complex, has entered phase II clinical trials for 
the treatment of non-muscular invasive bladder cancer. In this compound, the ligands are coordinated via nitrogen bonds, but in this paper, 
carbon-coordinated complexes are explored. Coordination of N-heterocyclic carbene (NHC) ligands to ruthenium is suspected to provide a 
different type of coordination complex in PCT. Tripodal and pyridazine NHC ligands were synthesized in this paper, with the tripodal ligand 
being more successfully produced.  
INTRODUCTION 
Development of photoactive drugs is a relatively new approach in 
chemotherapy. Current common chemotherapies fall short because 
of their general cytotoxicity to healthy cells as well as cancer cells. By 
controlling the location of the activated drug with light, the use of 
activated drugs gives hope to treat cancer patients without causing 
the burden of additional damage to healthy tissue. The use of light,  
oxygen, and drugs that act as photosensitizers is known as photody-
namic therapy (PDT).1, 2 PDT has been applied in the treatment of 
many cancers, including lung, esophagus, and skin.3 These are can-
cers easily accessible from the outside and easily exposed to light. In 
making these compounds, there are many desirable qualities: inert 
in the dark, active in the visible light region, and easily synthesized.3 
There are two types of photoprocesses in PDT.4 Type I photopro-
cesses involve the electron transfer from photosensitizer to ground-
state oxygen (3O2) to produce superoxide (O2-) and hydroperoxyl 
radicals (HO2-).4 These both cause biomolecule degradation and tis-
sue damage or destruction in the body.4 Type II PDT agents gener-
ate singlet oxygen via the energy transfer from the triplet state of the 
photosensitizer to the ground state of oxygen. Type II PDT agents 
target unsaturated lipids, amino acid side chains, and nitrogenous 
bases.4 PDT can also target cancer cells by binding molecules that 
attach to surface receptors that are extremely common on cancer 
cells.4 These molecules that photosensitizers can bind include anti-
bodies, peptides, proteins, epidermal growth factors, insulin, low-
density lipoproteins (LDL), carbohydrates, somatostatin, folic acid, 
and more.4 There has also been intracellular targeting of mitochon-
dria to promote apoptosis via the intracellular apoptotic pathway.4 
Ideally, photosensitizers should have the following qualities ac-
cording to Monro, et al.: (1) effective singlet oxygen generation even 
in hypoxic (low oxygen) environments, (2) large molar extinction 
coefficient for a wavelength specialized for a type of cancer, (3) spec-
ificity for tumor cells, (4) rapid clearance from the body, (5) inactiv-
ity in the dark (non-toxicity), (6) chemical stability, (7) availability 
for injection into the body (most predominantly by dissolution in 
aqueous solution), (8) easily synthesized and purified.4 Many tu-
mors survive in hypoxic environments or create hypoxic environ-
ments due to their density and affinity for glycolysis as a source of 
energy. This makes them difficult to treat with current PDT agents 
that rely on oxygen.  
Metal coordination complexes are advantageous for many rea-
sons: range of oxidation states, coordination numbers, variable ge-
ometries, multiple electronic transitions, lower-energy and longer-
lived triplet states, and oxygen-independent mechanisms of cell 
death.4 Low-energy triplet states are important, as the wavelengths 
of light used to excite the molecules are limited to the energy re-
quired to sensitize singlet oxygen (94.5 kJ).4 The many electronic 
transitions possible for transition metal complexes are ligand-to-
metal charge transfer (LMCT), intraligand charge transfer (IL), 
metal-centered charge transfer (MC), and metal-to-ligand charge 
transfer (MLCT).4  MLCT and IL are useful energy transitions in 
providing energy to convert ground-state oxygen to singlet oxygen. 
Availability of oxygen-independent mechanisms create the possibil-
ity of treating dense and hypoxic tumors. Coordination complexes 
can attack cancer cells via ligand dissociation independent of oxygen. 
Specific geometries are required to make an organometallic com-
pound light sensitive.1 Compounds with distorted octahedral geom-
etry dissociate from their ligands when exposed to light.1  
Current transition metal therapies include platinum amine com-
plexes. Cisplatin (cis-diamminedichloroplatinum(II)) intercalates 
into DNA and causes the cell to have difficulty in any processes in-
volving DNA. Nearly 50% of all cancer treatments are platinum-
based.4 Despite their relative effectiveness for certain cancers such as 
prostate cancer, they have many dangerous side effects. Platinum-
based drugs are renally toxic, myelosuppressive, neurotoxic, and oto-
toxic. Other side effects include nausea, vomiting, hair loss, pain, 
weakness, anemia, and anaphylactic-like reactions. Platinum thera-
peutics also have issues with degradation before they reach the target 
DNA and intrinsic or acquired resistance by cancer cells. One of the 
most common methods of resistance by cancer cells to cisplatin is 
decreased accumulation or increased efflux by copper-transporter 1 
and ATPases 7A/7B, respectively. Glutathione also binds and deac-
tivates cisplatin.3 Therefore, there are many qualities of platinum 
drugs that cause them to be harsh cancer treatments.
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Platinum(II) only has the ability to bind to four ligands at a time. 
Ruthenium, as is used in these experiments, is able to coordinate to 
six ligands at one time. This makes it a more flexible metal to use as 
a metal center. It is also in the same group as iron; this makes it more 
likely to be taken up by cells.5 Furthermore, there is the possibility of 
replacing the central ruthenium with iron after the complex has been 
created. This would make the drug less expensive to produce and 
more environmentally friendly. Ruthenium also has the advantage 
over platinum by being reductively activated in cells.6 In addition, 
ruthenium compounds are active against some cisplatin-resistant 
cell lines and have fewer side effects as they are more selective for 
cancer cells.6 
 
Figure 1. Structure of TLD1433. This figure has been borrowed from 
the literature.4 
The ruthenium complex TLD1433 (Figure 1) has reached phase 
II clinical trials for non-muscular invasive bladder cancer.4 The com-
plex participates in many electronic transitions. Its excitation by light 
brings it to the 1MLCT state that then relaxes to a 3IL state that cre-
ates a long-lived (~100s of microseconds) excited-state equilibrium 
with a 3IL state located on the thiophene conjugated ligand. This 
long-lived excited state can very efficiently generate 1O2 from the 3IL 
state. 4 In addition, this complex can participate in oxygen-independ-
ent mechanisms by electron transfer from the triplet intraligand 
charge transfer (3ILCT) state.4 
Three other ruthenium compounds have been tested in clinical 
trials: NAMI-A, KP1019, and KP1339 (Figure 2). Unfortunately, 
NAMI-A and KP1019 did not make it past phase II  clinical trials.6 
KP1339 is still under consideration in clinical trials.6 
 
Figure 2. Ruthenium complexes that have been through clinical trials.6 
All the ruthenium compounds shown above include at least one 
nitrogen ligand. In my experiments, one or more ligands are coordi-
nated via the carbon atom of a N-heterocyclic carbene (NHC). 
NHCs were chosen as ligands due to their strong 𝜎 donation, ability 
to make very stable compounds, and drastic effects on electronic 
properties, such as excited-state lifetimes, which are important for 
PDT. The resonance structures of the carbene used in my experi-
ments are shown in figure 3. NHCs also can engage in 𝜋-donation or 𝜋-backbonding.7 
 
Figure 3. Electron push diagrams illustrating resonance around the car-
bene. 
When the NHCs bind to a metal atom, they strongly donate to 
the metal, for example, pushing a trans-chloride away from the cen-
tral metal and making it more easily replaced (Figure 4). 
 
Figure 4. Lengthening of the M-Cl bond is emphasized to show the 
strong donation effect from the carbene to the metal and the weaken-
ing of the Cl-M bond. 
In this paper, the synthesis and characterization of imidazolium 
and pyridazolium ligands and their attempted coordination will be 
described.  
 
SYNTHESIS 
1,1,1-Tris[(p-toluenesulfonato)methyl]ethane (1A).  1,1,1-
Tris(hydroxymethyl)ethane (33.68 g) was dissolved in pyridine 
(100 mL) at 0 °C. p-Toluenesulfonyl chloride (164.0 g) was dis-
solved in pyridine (100 mL) and slowly added to the mixture. The
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Scheme 1. Reaction scheme of the tripod complexes stirred in the dark under nitrogen for 48 h. The solution was filtered through 
Celite and the filtrate was brown. The filtrate was cooled in dry ice and DI water was added. No precipitate formed.
flask was removed from the ice bath and set to stir at room tempera-
ture for 4 h. The slurry was mixed with HCl (200 mL) and methanol 
(100 mL). A gummy solid formed in the flask. Methanol was poured 
over the gummy mass and stirred until white solid precipitated. The 
white solid was vacuum dried overnight and then oven dried over-
night. 132.22 g of product collected.8-11 
1,1,1-Tris(bromomethyl)ethane (1B).  1A (46.03 g) and NaBr 
(83.02 g) were mixed in diethylene glycol (250 mL). The reaction 
mixture was heated to 145 °C and stirred by an overhead stirrer for 
48 h. The solution was washed with DI H2O (250 mL) and three 
times with ethyl ether (50 mL). The organic phase was dried with 
MgSO4, filtered, and evaporated to dryness. 15.56 g of brown oil was 
collected as product.12, 13 
1,1,1-Tris[(n-methylimidazole)methyl]ethane, 
[H3TIMEMe](PF6)3 (1C).  1B (1.02 g) was added to n-methylimid-
azole (2 mL) and heated to 150°C. The reaction mixture was stirred 
for 18 h under nitrogen. A peanut-butter-like precipitate formed in 
the bottom. The precipitate was washed with ethanol and white pre-
cipitate formed. The white solid was dissolved in methanol and 
NH4PF6 (1.95 g) was added. White powder precipitated (121 mg).12 
[(TIMEMe)2Ag3](PF6)3 (1D) Trial 1.  [H3TIMEMe](PF6)3 (200 
mg) was added to a solution of DMSO (20 mL) and Ag2O (97 mg). 
The reaction was stirred in the dark under nitrogen for 12 h at 75 °C. 
A white-yellow precipitate was obtained (199 mg) and stored in the 
dark.12
    [(TIMEMe)2Ag3](PF6)3 (1D) Trial 2.  [H3TIMEMe](PF6)3 (1.02 
g) was added to a solution of DMSO (100 mL) and Ag2O (496 mg). 
The reaction was stirred in the dark for 24 h at 75 °C. The slurry was 
filtered through Celite, but no precipitate collected in frit. DI water 
was added to filtrate to precipitate solid and washed with ether. No 
solid precipitated. The solution was vacuum dried and then put in an 
ice bath to condense, but no solid precipitated. No product was col-
lected. 
[(TIMEMe)2Ag3](PF6)3 (1D) Trial 3.  [H3TIMEMe](PF6)3 (1.00 
g) was added to a solution of DMSO (100ml) and Ag2O (486 mg). 
The reaction mixture was stirred in the dark under nitrogen for 18 h 
at 75 °C. It was taken off heat and chilled in an ice bath. The entire 
solution froze and was allowed to melt. The mixture was very gray. It 
was put back on heat for 20 h at 100 °C. The solution was filtered 
through Celite. The filtrate was put in an ice bath and lacked the gray 
color. After adding equal amounts of water, it was washed five times 
with ether (25 mL). It was then vacuum dried, and a white powder 
precipitated (716 mg).  
[(TIMEMe)2Ag3](PF6)3 (1D) Trial 4.  [H3TIMEMe](PF6)3 (2.92 
g) was added to a solution of Ag2O (1.44 g) and DMSO (100 mL). 
The reaction mixture was stirred at 75 °C for 18 h under nitrogen in 
the dark. The solution was filtered through Celite, and grey solid col-
lected in the frit. The filtrate was brown. Filtrate was chilled in an ice 
bath for 20 min, and then DI water was added. The solution was 
stirred in the ice bath for 40 min. It was then poured through a frit, 
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but nothing collected in the frit. More water was added, and the so-
lution chilled in the ice bath again. No precipitate formed.  
[(TIMEMe)2Ag3](PF6)3 (1D) Trial 5.  [H3TIMEMe](PF6)3 (1.0 
g) was added to a solution of Ag2O (1.00 g) and DMSO (100 mL). 
The reaction mixture was heated to 100 °C and stirred in the dark 
under nitrogen for 48 h. The solution was filtered through Celite, 
and the filtrate was brown. The filtrate was cooled in dry ice, and DI 
water was added. No precipitate formed.  
[(TIMEMe)2Ag3](PF6)3 (1D) Trial 6.  [H3TIMEMe](PF6)3 (200 
mg) was added to a solution of Ag2O (101 mg) and dry DMSO (20 
mL) in a Schlenk flask that had been dried in an oven at 120 °C. The 
reaction mixture was stirred in the dark at 100 °C for 15 h under ni-
trogen. The solution was filtered through Celite, and the filtrate 
came out clear. The filtrate was cooled to room temperature, and an 
equal amount of DI water was added. The mixture chilled in an ice 
bath in the dark for 2 h. Ether was then added and stirred in the flask. 
Brown precipitate collected. 
(1E) Trial 1. [Ru2Cl4(p-cymene)2] (54 mg) was added to a mix-
ture of 1D Trial 1 (92 mg) in dichloromethane (30 mL). The reac-
tion mixture was stirred for 20 h at room temperature in the dark. 
The suspension was filtered through Celite and washed with di-
chloromethane. Hexanes were added to precipitate the product. A 
light orange solid was collected after vacuum drying (42 mg). The 
product was insoluble in chloroform but soluble in acetone. A 1H 
NMR was run in acetone. 
(1E) Trial 2.  [H3TIMEMe](PF6)3 (230 mg) was added to a solu-
tion of Ag2O (54 mg) and acetonitrile (10 mL). The reaction mix-
ture was stirred at 60 °C under nitrogen, in the dark, for 5 h. At this 
point, Ru2Cl4(p-cymene)2 (192 mg) was added to the reaction mix-
ture. After 18 h of stirring in the same conditions, it was cooled to 
room temperature. The solution was filtered through Celite. The fil-
trate was red wine-colored, and there was white precipitate on the 
Celite. NH4PF6 (32 mg) was added to the solution and stirred for 20 
min. The solution was filtered through Celite, and some white pow-
der filtered out. The filtrate was still red wine-colored. The acetoni-
trile was removed on the rotary evaporator. The residue was washed 
with ethanol. Yellow color came out in the ethanol washes. The eth-
anol was decanted, and the remaining solution dried on the rotary 
evaporator. The remaining solution was then washed with ether, and 
some red color was taken off by the ether. The solution was then 
dried on the rotary evaporator again, and 42 mg of red product re-
mained. 14 
(1E) Trial 3.  [H3TIMEMe](PF6)3 (235 mg) was added to a solu-
tion of Ag2O (52 mg) and acetonitrile (10 mL). The reaction mix-
ture was heated to 60 °C for 48 h. The slurry was brown, and black 
chunks precipitated. Ru2Cl4(p-cymene)2 (203 mg) was added to the 
solution, and heating continued for 3 d. The solution, which had 
turned red, was allowed to cool to room temperature. It was filtered 
through Celite, and NH4PF6 (44 mg) was added to the filtrate. The 
solution stirred for 20 min and was filtered through Celite. The fil-
trate was dried on the rotary evaporator and then washed with etha-
nol (three times with 5 mL). The ethanol turned yellow. The solu-
tion was swirled with ether (three times with 5 mL), and the ether 
layer was decanted. What remained in the flask was a red viscous oil. 
The oil was dried on the rotary evaporator, and bubbles formed that 
hardened. The red solid was able to be scraped out of the flask and 
dissolved in acetone for 1H NMR. 308 mg of red product was col-
lected. Dichloromethane was added to the product and turned or-
ange; not all dissolved in the dichloromethane. The red colored res-
idue remained solid. The red solid was soluble in acetone. Crystalli-
zation of each part was attempted in acetone/ether and dichloro-
methane/ether. Small crystals appeared in the dichloro-
methane/ether set up after a few days. X-ray crystallography was per-
formed by Dr. Parkin. 
(1E) Trial 4.  [H3TIMEMe](PF6)3 (270 mg) was added to a solu-
tion of Ag2O (70 mg) and acetonitrile (10 mL). The reaction mix-
ture was heated to 50 °C in the dark under nitrogen for 44 h. After 
44 h, Ru2Cl4(p-cymene)2 (214 mg) was added. The mixture stirred 
at 50 °C for 4 d. The solution was filtered through Celite which re-
moved a white precipitate. The filtrate was placed on the rotary evap-
orator, and a red oil remained. Crystallization was set up in ace-
tone/ether and DMSO/ether. The acetone/ether crystallization 
produced small red needle crystals. X-ray crystallography was per-
formed by Dr. Parkin.  
(1F) Trial 1.  1D Trial 1 (105 mg) was added to a solution of 
RuCl2(DMSO)4 (86 mg) and dichloromethane/THF (1:1 ratio). 
The reaction mixture was stirred overnight at 60 °C under nitrogen 
in the dark. The solution was filtered through a glass frit, and acetone 
(30 mL) was poured over the collected powder three times. The fil-
trate was green, and a gray/white powder collected in the frit. Ace-
tone was added to the filtrate to see if product would precipitate – 
no signs of precipitate. The solid in the frit was washed with acetone; 
this wash turned gray, but the powder remained gray/white. The 
grey liquid was rotary evaporated and then evaporated to dryness on 
the house vacuum. 1H NMR was taken of the product in acetone as 
it was insoluble in chloroform. 
(1F) Trial 2.  1D Trial 3 (158 mg) was added to a solution of 
RuCl2(DMSO)4 and dichloromethane/THF (1:1 ratio). The reac-
tion mixture was stirred at 60 °C for 58 h in the dark under nitrogen. 
The solution was filtered through a glass frit. The yellow residue was 
mixed with acetone, and then the acetone layer was decanted, and 
the residue vacuum dried. 1H NMR of the yellow residue was per-
formed in acetone. The solid that collected in the frit was washed 
with acetone. 1H NMR in acetone was taken before and after this ac-
etone wash. 
(1F) Trial 3. 1D Trial 3 (481 mg) was added to a solution of 
RuCl2(DMSO)4 in dichloromethane/THF (1:1 ratio, 24 mL). The 
reaction mixture was stirred at 60 °C under nitrogen in the dark for 
18 h. The solution turned orange and was poured over a glass frit. 
The filtrate was mixed with acetone, but no product precipitated. Ac-
etone was poured over the solid in the frit. The solid was vacuum 
dried and collected as product (466 mg). 1H NMR was performed 
in DMSO.   
(1F) Trial 4. 1D Trial 3 (103 mg) was added to a solution of 
RuCl2(DMSO)4 (80 mg) and DMSO (5 mL). The reaction mixture
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Scheme 2. Reaction scheme of the pyridazine complexes. * indicates that the reaction has not been tested to date.
was heated to 110 °C and stirred in a pressure flask for 24 h in the 
dark. The solution turned dark yellow. NH4PF6 was added. No pre-
cipitate. 10 mL of water was added, and still no precipitate formed.  
(1F) Trial 5.  Product from reaction 1F Trial 3 (191 mg) was as-
sumed to be unreacted 1D Trial 3 and added to a solution of 
RuCl2(DMSO)4 (148 mg) and acetonitrile (50 mL). The reaction 
mixture was refluxed under nitrogen in the dark for 5 d. During this 
time, multiple TLCs were performed to assess the progress of the re-
action. TLC #1  (silica stationary phase, KNO3 10% aq./90% MeCN 
mobile phase) showed movement of the Ru reagent spot, but no 
movement of the silver reagent or product spot. TLC #2 (silica sta-
tionary phase, acetonitrile mobile phase) showed no movement of 
any of the spots. TLC #3 (silica stationary phase, acetone mobile 
phase) showed no movement of any of the spots. TLC #4 (silica sta-
tionary phase, hexane mobile phase) showed no movement of spots. 
The initially pale-yellow product that had been removed from the 
reaction mixture turned pink. After 1 h of heating, the reaction color 
turned darker yellow. After it was cooled (after 5 d), it was a pink 
colored solution. It was evaporated to dryness on vacuum line, and 
the product dried into a dark purple/red solid. The solid was insolu-
ble in acetone, but soluble in DMSO. Crystallization was set up. 
(1F) Trial 6. [H3TIMEMe](PF6)3 (236 mg) was added to a solu-
tion of RuCl2(DMSO)4 (34 mg) and 1,2-ethanediol (7 mL) in a 
pressure flask. The reaction mixture stirred at 180 °C in the dark for 
5 h. The solution was filtered through a frit, and white and black 
powder stayed in the frit. The solids were collected and vacuum 
dried. They were soluble in DMSO, and 1H NMR was performed in 
DMSO. 
3,6-Dimethylpyridazine (2A). 2,5-Hexanedione (30 mL, 255 
mmol) and hydrazine hydrate (15 mL, 468 mmol) were added to 
ethanol (250 mL) and heated to reflux for 1 h. The ethanol was 
evaporated by rotary evaporation, and a viscous yellow oil was left. 
Pd on C (1.74 g) and benzene (250 mL) were added to the yellow 
oil and stirred and heated to reflux (~70 °C) for 18 h. The benzene 
was evaporated. Then the remaining solution was distilled, and the 
product came off at a vapor temperature between 60 and 70 °C. The 
product was a light-yellow oil. 1H NMR was taken in chloroform. 
The product was redistilled because the 1H NMR looked impure. 
Fraction one of this distillation came off at 40-60 °C. Fraction two 
came off around 64 °C, and then the vapor temperature dropped. 
Fraction two was collected as product (5.4 g).15 
3,6-Bis(chloromethyl)pyridazine (2B). 3,6-Dimethylpyri-
dazine (1.042 g) was heated to reflux in chloroform (100 mL). Once 
reflux was reached, trichloroisocyanuric acid (1.883 g) was added. 
The reaction mixture turned dark yellow, then pale yellow. After 30 
min, the mixture looked like coconut milk. The solution was refluxed 
for 1 h and then cooled. It was then filtered through Hyflo Celite. 
The filtrate was washed with NaOH (27 mL) twice, DI H2O (35 
mL) twice, HCl (27 mL) once, and then DI H2O (35 mL) again. 
The organic layer was dried with MgSO4. The solution was clear and 
slightly yellow. Chloroform solvent was evaporated off at 0 °C. 
There was a light brown solid left in the bottom. This solid was puri-
fied with flash chromatography (1:4 acetone to pentane). Dark yel-
low color stayed at the top of the column. 100% yield (1.71 g) as-
sumed and moved on to the next step as product is extremely heat 
sensitive.16 
3,6-Bis(bromomethyl)pyridazine. 3,6-Dimethylpyri-dazine 
(0.5 g) and bromine (1.5 g) was added to acetic acid (35 mL) and 
heated to 60 °C for 4 h. TLC was performed with 40:60 mL ace-
tone:pentane mobile phase. This TLC was uninformative. The mix-
ture was moved to the rotary evaporator. The product was a brown 
solid. It was washed with ethyl acetate. Sodium bicarbonate (20 mL 
saturated) and thionyl chloride (1 g) were added. This mixture was 
2A 2B 
2C 2D * 
* 
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moved to a separatory funnel, and the ethyl acetate layer was col-
lected. This organic layer was dark brown. It was moved to the house 
vacuum, and a gum was left as the product. Some part of it was solu-
ble in chloroform, and this part was evaluated by 1H NMR. 
3,6-Bis(tert-butylaminomethyl)pyridazine (2C). 3,6-
Bis(chloromethyl)pyridazine (1.71 g) and tert-butylamine (9.76 
mL, 93 mmol) were mixed in acetonitrile (50 mL) for 35 h at room 
temperature. The solution turned orange and was moved to the 
fridge. Acetonitrile was evaporated off on the house vacuum line 
while sitting in an ice bath. A red gummy solid remained (3 g). 1H 
NMR done in chloroform.17 
3,6-Bis(tert-butylformamidomethyl)pyridazine (2D). 3,6-
Bis(tert-butylaminomethyl)pyridazine (3 g) was added to formic 
acid (21 mL, 557 mmol) and stirred for 1.5 h. The mixture turned 
orange-brown. Acetic acid (21 mL) and distilled water (30 mL) 
were then added and stirred for 30 min. The solvent was evaporated 
off at 0 °C. The flask was then filled with nitrogen and placed in the 
fridge. 1H NMR was performed in acetonitrile. The 1H NMR didn’t 
show good differentiation between peaks. Cold acetonitrile was 
added to the flask and stirred for 10 min and then removed at 0 °C 
under vacuum. Another H NMR was performed in chloroform. 5.46 
g of brown oil was collected.18 
 
RESULTS 
1H NMR data is displayed in the supporting information included 
at the end of the paper. TLC data is not included in this paper. 
 
 
Figure 5. Crystal structure of the product of the red needle crystals pro-
duced by reactions 1E Trial 4 and 1E Trial 3. 
X-ray crystallography was performed by Dr. Sean Parkin at the 
University of Kentucky. The crystals tested were bright red, needle 
crystals grown as described in the synthesis section. The crystal 
structure is shown in Fig. 6.  
 
DISCUSSION 
The successful synthesis of 1,1,1-tris[(p-toluenesulfonato)me-
thyl]ethane was confirmed by comparison of its 1H NMR (Fig. 7) 
with the literature. The 1H NMR from this experimental spectrum 
shows peaks at  7.70 (d, 6H), 7.34 (d, 6), 3.77 (s, 6), 2.47 (s, 9), 0.89 
ppm (s, 3H); whereas, the literature peaks are at 7.70 (d, 6H), 7.38 
(d, 6H), 3.75 (s, 6H), 2.46 (s, 9H), 0.86 (s, 3H).19 The product was 
obtained as a white solid in a 79% yield. The next step in this synthe-
sis, 1B, appears less successful. The 1H NMR for 1B did not match 
previously reported NMR vaues.20 For example, my product showed 
peaks and integral values of 3.70 (s, 4H), 3.5 (s, 5H), 1.29 (s, 3H), 
and 1.25 (s, 1H), which did not agree with previously reported peaks 
at 3.44 (s, 6H) and 1.22 (s, 3H).  All the tosylates seem to be absent 
from the product as there are no peaks further down than 4 ppm that 
could be assigned to the starting material. This could show that there 
is asymmetry in the compound. This 1H NMR data suggests the de-
sired product was not formed under these reaction conditions.  
However, upon the attempted conversion of this sample of 1B to 
1C, a 1H NMR spectrum was obtained that closely matched previ-
ously reported spectrum for 1C (Fig. 9). The experimental 1H NMR 
peaks were at 9.13 (s, 3H), 7.8 (s, 3H), 7.69 (s, 3H), 4.27 (s, 5H), 
3.90 (s, 9H), 0.94 ppm (s, 3H); whereas, the literature reported 
peaks at 9.12 (s, 3H), 7.82 (s, 3H), 7.68 (s, 3H), 4.26 (s, 6H), 3.89 
(s, 9H), 0.93 ppm (s, 3H).12 This supports that 1B had successfully 
been produced but didn’t show the same peaks as in the literature. 
The workup of 1C may also have been successful in removing any of 
the contaminant from 1B. Therefore, the synthesis of 1,1,1-tris[(N-
methylimidazole)methyl]ethane (1C) as presented in this paper 
is highly reproducible in yielding the desired product. The methods 
and 1H NMR presented in this paper show the purest product from 
the many syntheses. 
For the coordination of this ligand to a metal center, two different 
ruthenium starting materials were chosen based on ease of synthesis, 
good reactivity, and their presence in the literature.21, 22 The syn-
thetic strategy to form ruthenium complexes with  1C consisted of 
reacting 1C with Ag2O to form an Ag-NHC complex, followed by 
transmetallation from Ag to Ru(II). The formation of Ru(II) com-
plexes by this method proved to be plagued with problems. Some 
reactions yielded no precipitate (1F Trial 4, 1D Trial 2, 1D Trial 4, 
1D Trial 5), and the solution was not evaluated. Some of the prob-
lems can be attributed to difficulties forming the Ag-NHC interme-
diate, [(TIMEMe)2Ag3](PF6)3 (1D).  One possible cause of this dif-
ficulty is likely due to poor quality Ag2O caused by age and photo-
decomposition.  This suspect Ag2O was used for 1D Trial 1 as well 
as a second trial, but failed to yield product, and was replaced with a 
new bottle. Even with new Ag2O, the formation of 1D was unpre-
dictable, and the product was difficult to store. Storage away from 
light was vital, as 1D rapidly decomposed from a white solid to a gray 
solid upon exposure to light, which is common for silver complexes 
and salts. For these reasons, I began to use a previously reported 
method where the silver complex was form in situ followed by the 
addition of the Ru(II) starting material.  
When reacting Ru2Cl4(p-cymene)2 with 1D, 1E Trial 1 showed 
an 1H NMR that was extremely similar to the 1H NMR spectrum of 
[(TIMEMe)2Ag3](PF6)3 reported by Hu.12 1H NMR of 
[(TIMEMe)2Ag3](PF6)3 by Hu: 7.55 (s, 3H), 7.49 (s, 3H), 4.44 (s, 
3H), 4.20 (s, 3H), 3.90 (s, 9H), 1.24 ppm (s, 3H). This shows that 
the reaction likely did not proceed past the silver step as there was 
no evidence of p-cymene. For this reason, the product was reused in 
reaction 1F Trial 5. The ruthenium product was not crystallized suc-
cessfully, but 1H NMR showed that at least there had been a reaction. 
The peaks appear to be in the right range (between 7 and 8 ppm, 
around 4 ppm, and 1 ppm as in the silver complex) for the ligand to 
be attached. Therefore, it is possible that the product may be hiding 
in that spectrum. The shifts from the silver numbers may be due to 
the interactions with ruthenium. However, it would need to be puri-
fied to be more conclusive. The many peaks may also be due to only 
a few of the tripod arms being attached. This would create asym-
metry and more peak splitting. 
In reactions 1F Trial 6 and 1F Trial 2, the product was clearly not 
in the 1H NMR sample. Only solvent and unintended products had 
been collected. In multiple 1F and 1E reactions, I may have collected 
the wrong product. Early on, some of the reactions produced 
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precipitate that I then collected as product. However, the actual 
product may have stayed in solution. This precipitate was most likely 
AgCl from a reaction between 1D and chloride ions attached to the 
metal center.  Other salts like this may have precipitated and been 
collected as product. 
A crystal structure collected from reactions 1E Trial 4 and 1E 
Trial 3 shows that the intended product did not crystallize, but a 
chloride ion was abstracted from the ruthenium starting material 
(Fig. 6). It is possible that the intended product did form, but there 
is no evidence of this as 1H NMR was not performed. As the 
Ru2Cl4(p-cymene)2 is the starting material that self-reacted, the 
RuCl2(DMSO)4 seems to be a good alternative starting material. 
From the 1H NMR data (Fig. 12, 14, 15) on the 1F compounds, it 
seems likely that the product could be obtained as there were a mul-
titude of peaks in the 7-8 ppm, 4 ppm, and 1 ppm range. The ease of 
synthesis of the precursor ligand also supports further reactions with 
RuCl2(DMSO)4. Future work with this ligand and ruthenium source 
could result in complexes with very interesting characteristics of an-
ticancer ruthenium complexes. 
The synthesis of 3,6-dimethylpyridazine (2A) was very easy to 
perform, and the product could be obtained in high purity by vac-
uum distillation followed by crystallized on cold storage. The follow-
ing reaction to produce 3,6-bis(chloromethyl)pyridazine (2B) 
was much more difficult. This reaction was run many times with dif-
ferent temperatures and reaction times. Trichloroisocyanuric acid 
seemed to be the most common chlorination method for this reac-
tion (2B), but perhaps it is not the best. The product was difficult to 
identify in a 1H NMR or TLC. As it was so heat sensitive, the product 
was assumed to be produced, and the next step was immediately 
done as the 3,6-bis(tert-butylaminomethyl)pyridazine was more 
stable and, thus, could be more easily tested. The spectrum of 3,6-
bis(tert-butylaminomethyl)pyridazine (Fig. 19) resembles the 
literature values.18 1H NMR of 3,6-bis(tert-butylaminome-
thyl)pyridazine  from the literature reported peaks at 7.52 (s, 2H), 
4.05 (s, 4H), 1.88 (s, 2H), 1.19 ppm (s, 18H).18 My spectrum shows 
peaks at 7.56 (s, 2H), 4.11 (s, 5H), 1.32 (s, 21H), 1.26 (s, 10H), 1.18 
ppm (s, 5H). For some peaks, such as 4.05 ppm, this could be due to 
error in choosing the proper range for the integral. For other peaks, 
it may be that there is starting material or other contaminants in the 
same locations that raise the peaks. The issue could also be that the 
compound only had one tert-butyl-amine group attached, and the 
other side was a methyl group due to the loss of a chloride. This 
would lead to asymmetrical peaks. 
My products have been overchlorinated and underchlorinated, 
and it is difficult to determine the perfect reaction conditions. The 
product is highly heat sensitive, and so the solvent cannot be re-
moved on the rotary evaporator.23 Thus, the house vacuum with an 
ice bath was used. However, this evaporation takes a long time; many 
times I left it overnight to dry. The compound could have self-re-
acted during this time. It is also frustrating that the product is heat 
sensitive, yet the reaction is run at reflux. This could cause the prod-
uct to self-react as soon as it is produced. During one run of this ex-
periment, the reaction mixture heated for 60 min, and a small sample 
for 1H NMR was taken every 10 min to monitor reaction comple-
tion. Unfortunately, this proved to be unfeasible as the workup for 
the reaction removed so much of the sample that nothing was left to 
put in the NMR tube for each of the six samples. The reaction was 
also difficult to monitor via TLC on silica; though, in theory, this 
should be possible. 
    A different method may be a better way to produce the halogen-
ated product. For the reasons discussed above, bromination of 2A 
had been attempted but failed under the reaction conditions men-
tioned in the synthesis section. The 1H NMR of the bromination, 
3,6-bis(bromomethyl) pyridazine, showed starting material only. 
Longer reaction times and a higher temperature may be used to push 
this reaction to completion. Different bromine reactants may also be 
tested. One that I am particularly interested in testing is NBS; this 
reagent was not used at the time because it was not readily available 
in the lab. Perhaps also, if the methyl group can be hydroxylated, the 
same bromination used in the tripod reactions can be used to bro-
minate the molecule. However, this method may prove more diffi-
cult than hypothesized. 
The synthesis of 3,6-bis(tert-butylformamidomethyl) pyri-
dazine (2D) appears the be unsuccessful as the 1H NMR spectrum 
is not analogous to the literature (Fig. 20). The experimental 1H 
NMR spectrum showed peaks at 7.95 (d, 2H), 7.8 (d, 2H), 7.5 (s, 
1H), 7.02 (s, 2H), 5.29 (s, 3H), 4.12 (s, 1H), 2.77 (s, 1H), 1.93 (s, 
10H), 7.32 (s, 7H), 1.24 (s, 11H), 1.19 (s, 18H), 1.18 ppm (s, 5H). 
The literature 1H NMR for the compound has peaks at 10.22 (s, 
2H), 8.35 (s, 2H), 7.46 (s, 2H), 1.79 ppm (s, 18H). The experi-
mental 1H NMR lacks the 10 ppm peak, which is a big indicator that 
the product was not present in the reaction I ran. This is likely due 
to the impurity of the starting material. 
 
CONCLUSION 
In conclusion, the reactions illustrated in this paper had varying 
success. The tripodal ligands were easy to synthesize, but the pyri-
dazine ligands were not. Different methods are needed to coordinate 
the tripodal ligand to the ruthenium. Different methods are also 
needed to form the 3,6-Bis(chloromethyl)pyridazine. Future goals 
for ruthenium complex synthesis are to form a tripod ruthenium 
complex and find a better method for halogenation of 3,6-dime-
thylpyridazine.  
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SUPPORTING INFORMATION (1H NMR SPECTRA) 
 
Figure 6. 1H NMR of 1,1,1-tris[(p-toluenesulfonato)methyl]ethane (1A) in chloroform. 
 
Figure 7. 1H NMR of 1,1,1-tris(bromomethyl)ethane (1B) in chloroform. 
 
Figure 8. 1H NMR of 1,1,1-tris[(n-methylimidazole)methyl]ethane, [H3TIMEMe](PF6)3 (1C) in DMSO. 
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Figure 9. 1H NMR of 1E Trial 1 in acetone. 
 
Figure 10. 1H NMR of 1E Trial 2 in DMSO. 
 
 
Figure 11. 1H NMR of 1F Trial 1 in acetone. The peaks and integrals are very similar to what Hu presented as the silver compound 
[(TIMEMe)2Ag3](PF6)3.12 
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Figure 12. 1H NMR of 1F Trial 2 yellow filtrate in acetone. 
 
 
Figure 13. 1H NMR of 1F Trial 3 solid in DMSO prior to acetone wash. The peaks and integrals are very similar to what Hu presented as the silver 
compound [(TIMEMe)2Ag3](PF6)3.12 
 
Figure 14. 1H NMR of 1F Trial 5 in DMSO. 
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Figure 15. 1H NMR of solid from 1F Trial 6 in DMSO. 
 
Figure 16. 1H NMR of 3,6-dimethylpyridazine (2A) in chloroform. 
 
Figure 17. 1H NMR of 3,6-bis(bromomethyl)pyridazine (2B) in chloroform. 
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Figure 18. 1H NMR of 3,6-bis(tert-butylaminomethyl)pyridazine (2C) in chloroform. 
 
 
Figure 19.  1H NMR of 3,6-bis(tert-butylformamidomethyl)pyridazine (2D) in chloroform.
 
